Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1999; 92(Suppl 37): 2–12.
PMCID: PMC1297017

The practical application and interpretation of simple lung function tests in cystic fibrosis.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.6M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996 Jul 18;335(3):179–188. [PubMed]
  • Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koëter GH, Dekhuijzen PN, Sluiter HJ. Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax. 1992 Jun;47(6):429–436. [PMC free article] [PubMed]
  • Waalkens HJ, Merkus PJ, van Essen-Zandvliet EE, Brand PL, Gerritsen J, Duiverman EJ, Kerrebijn KF, Knol KK, Quanjer PH. Assessment of bronchodilator response in children with asthma. Dutch CNSLD Study Group. Eur Respir J. 1993 May;6(5):645–651. [PubMed]
  • Taylor MR. Asthma: audit of peak flow rate guidelines for admission and discharge. Arch Dis Child. 1994 May;70(5):432–434. [PMC free article] [PubMed]
  • Miller MR, Pincock AC. Predicted values: how should we use them? Thorax. 1988 Apr;43(4):265–267. [PMC free article] [PubMed]
  • Hamm H, Light RW. The pleura: the outer space of pulmonary medicine. Eur Respir J. 1997 Jan;10(1):2–3. [PubMed]
  • Redline S, Wright EC, Kattan M, Kercsmar C, Weiss K. Short-term compliance with peak flow monitoring: results from a study of inner city children with asthma. Pediatr Pulmonol. 1996 Apr;21(4):203–210. [PubMed]
  • Studnicka M, Frischer T, Neumann M. Determinants of reproducibility of lung function tests in children aged 7 to 10 years. Pediatr Pulmonol. 1998 Apr;25(4):238–243. [PubMed]
  • Braggion C, Pradal U, Mastella G, Coates AL, Milic-Emili J. Effect of different inspiratory maneuvers on FEV1 in patients with cystic fibrosis. Chest. 1996 Sep;110(3):642–647. [PubMed]
  • Koller DY, Nilsson M, Enander I, Venge P, Eichler I. Serum eosinophil cationic protein, eosinophil protein X and eosinophil peroxidase in relation to pulmonary function in cystic fibrosis. Clin Exp Allergy. 1998 Feb;28(2):241–248. [PubMed]
  • Wojnarowski C, Eichler I, Gartner C, Götz M, Renner S, Koller DY, Frischer T. Sensitization to Aspergillus fumigatus and lung function in children with cystic fibrosis. Am J Respir Crit Care Med. 1997 Jun;155(6):1902–1907. [PubMed]
  • Høiby N, Koch C. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax. 1990 Nov;45(11):881–884. [PMC free article] [PubMed]
  • Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol. 1997 May;23(5):330–335. [PubMed]
  • Mahadeva R, Webb K, Westerbeek RC, Carroll NR, Dodd ME, Bilton D, Lomas DA. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ. 1998 Jun 13;316(7147):1771–1775. [PMC free article] [PubMed]
  • Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest. 1998 May;113(5):1230–1234. [PubMed]
  • Gurney JW, Habbe TG, Hicklin J. Distribution of disease in cystic fibrosis: correlation with pulmonary function. Chest. 1997 Aug;112(2):357–362. [PubMed]
  • Høiby N. Isolation and treatment of cystic fibrosis patients with lung infections caused by Pseudomonas (Burkholderia) cepacia and multiresistant Pseudomonas aeruginosa. Neth J Med. 1995 Jun;46(6):280–287. [PubMed]
  • Webb AK, Govan JR. Burkholderia cepacia: another twist and a further threat. Thorax. 1998 May;53(5):333–334. [PMC free article] [PubMed]
  • Vu-Thien H, Moissenet D, Valcin M, Dulot C, Tournier G, Garbarg-Chenon A. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center. Eur J Clin Microbiol Infect Dis. 1996 Nov;15(11):876–879. [PubMed]
  • Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, Heaf DP, van Saene H, Hart CA. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996 Sep 7;348(9028):639–642. [PubMed]
  • Ledson MJ, Gallagher MJ, Corkill JE, Hart CA, Walshaw MJ. Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia. Thorax. 1998 May;53(5):432–436. [PMC free article] [PubMed]
  • Leeming JP, Pryce-Roberts DM, Kendrick AH, Smith EC. The efficacy of filters used in respiratory function apparatus. J Hosp Infect. 1995 Nov;31(3):205–210. [PubMed]
  • Marchant J, Bush A. Prevention of cross infection during outpatient spirometry. Arch Dis Child. 1995 Feb;72(2):156–158. [PMC free article] [PubMed]
  • Brand PL, Kerstjens HA, Postma DS, Sterk PJ, Quanjer PH, Sluiter HJ, Dijkman JH, van Herwaarden CL, Hilvering C, Jansen HM, et al. Long-term multicentre trial in chronic nonspecific lung disease: methodology and baseline assessment in adult patients. Dutch CNSLD Study Group. Eur Respir J. 1992 Jan;5(1):21–31. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press